UBS/CALL/IDORSIA/4.006/0.1666/20.12.24 Stock

WIDIFU

CH1280380788

Market Closed - Bid/Ask 11:20:00 2024-07-02 EDT			After market 11:15:00
0.11 ^CHF	+10.00%		0.105	-4.55%

3 months	-42.11%
6 months	-21.43%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/4.006/0.1666/20.12.24

Latest news about IDORSIA LTD

New semester, new state of mind	07-01
Idorsia Wins European Commission's Nod for Resistant Hypertension Treatment	07-01	MT
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension	07-01	GL
Idorsia Ltd Receives Approval from the European Commission for JERAYGO?	07-01	CI

More news

Quotes 5-day view

Date	Price	Change

Delayed Quote Swiss Exchange

Last update July 02, 2024 at 11:20 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	WIDIFU
ISIN	CH1280380788
Date issued	2023-09-18
Strike	4.006 CHF
Maturity	2024-12-20 (170 Days)
Parity	6 : 1
Emission price	0.23 CHF
Emission volume	N/A
Settlement	physique
Currency	CHF

Technical Indicators

Highest since issue	0.26 CHF
Lowest since issue	0.07 CHF
Delta	0.54x
Omega	1.803
Premium	121.82x
Gearing	3.32x
Moneyness	0.5217
Difference Strike	1.916 CHF
Difference Strike %	+47.83%
Spread	0.03 CHF
Spread %	25.00%
Theoretical value	0.1050
Implied Volatility	183.06 %
Total Loss Probability	87.29 %
Intrinsic value	0.000000
Present value	0.1050
Break even	4.636 CHF
Theta	-0x
Vega	0x
Rho	0x

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company

Ratings for Idorsia Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Consensus: Idorsia Ltd

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.28 CHF

Average target price

1.692 CHF

Spread / Average Target

-25.77%

Consensus